First, to learn how to say these pharma names of these emerging therapies
Daclizumab (Dac-li-zu-mab) (trade name Zenapax)
is a therapeutic humanized monoclonal antibody. It is used to prevent rejection in organ transplantation, especially in kidney transplants. The drug is also under investigation for the treatment of multiple sclerosis.
Read more here
is a humanized anti-CD20 monoclonal antibody. It targets mature B lymphocytes and hence is an immunosuppressive drug candidate. It is under development by Hoffmann–La Roche's subsidiary Genentech, and Biogen Idec.
Ocrelizumab in MS: Encouraging Long-term Data